Oral immunization with Listeria monocytogenes vaccine enhances immunotherapy for protective immunity in murine models of colorectal cancer

Lei, Xinyuan, Yu, Yangle, Chung, Charlie, Qiu, Zhijuan, Zhang, Yue, Chu, Timothy H, Li, Xinran, Yang, Rin, Ozler, Khadir A, Burgac, Mami, Westcott, Peter MK, Beyaz, Semir, Sheridan, Brian S (February 2026) Oral immunization with Listeria monocytogenes vaccine enhances immunotherapy for protective immunity in murine models of colorectal cancer. Journal for ImmunoTherapy of Cancer, 14 (2). e011570-e011570. ISSN 2051-1426

[thumbnail of 10.1136.jitc-2025-011570.pdf] PDF
10.1136.jitc-2025-011570.pdf - Published Version
Available under License Creative Commons Attribution Non-commercial.
Download (12MB)

Abstract

BACKGROUND: Colorectal cancer (CRC) is a leading cause of cancer-related death and remains a significant global health challenge. Cancer vaccines have emerged as a promising immunotherapy for long-term tumor control. While Listeria monocytogenes (Lm)-based intravenous vaccines can generate tumor-reactive CD8 T cells, clinical trial success has been limited. Here, we sought to determine whether in vivo targeting of gastrointestinal tissues with foodborne delivery of Lm-based cancer vaccines controlled tumor growth in murine models of CRC. METHODS: The ActA and InlB virulence genes were deleted from a mouse-adapted Lm strain expressing ovalbumin and containing an internalin A mutation (InlAM Lm-ova) that allows epithelial cell invasion of mice to generate an oral vaccine administered via consumption of inoculated bread. Immunogenicity and safety were tested in C57Bl/6 mice. Vaccine efficacy was evaluated with CRC tumors delivered by colonoscopy-guided orthotopic transplantation into the colon submucosa. Microsatellite instability high MC38 cell line expressing ovalbumin or genetically engineered microsatellite stable AKPS (Apc KO Kras G12D Trp53 KO Smad4 KO) organoids expressing low levels of ovalbumin (loSIIN) were used. Vaccines were tested in prophylactic and therapeutic settings and in the context of immune checkpoint inhibitors (ICI). RESULTS: Oral immunization induced a robust CD8 T cell response that was similar in magnitude and phenotype to the fully virulent Lm. Immunized mice did not lose weight, and Lm was contained to intestinal tissues. Mice prophylactically immunized with the vaccine were protected from CRC tumors. Therapeutic immunization of mice bearing loSIIN AKPS tumors revealed curtailed growth of the local tumor but did not improve survival. Immunization with anti-programmed cell death protein-1 and anti-cytotoxic T-lymphocyte-associated protein 4 controlled tumors when coupled with therapeutic immunization. Protection correlated with accumulation of ova-specific CD8 T cells within the tumor. CONCLUSIONS: Oral Lm-based cancer vaccines targeting CRC elicit robust, widely disseminated, and persistent tumor-specific immune responses in mice. These vaccines limit CRC development when administered prophylactically and provide tumor control when administered therapeutically with ICI. Thus, oral delivery of Lm-based cancer vaccines coupled with ICI may provide improved control of CRC progression in clinical application.

Item Type: Paper
Subjects: diseases & disorders > cancer
diseases & disorders
organism description > animal
diseases & disorders > cancer > cancer types > colorectal
organism description > animal > mammal
organism description > animal > mammal > rodent > mouse
organism description > animal > mammal > rodent
diseases & disorders > cancer > cancer types
CSHL Authors:
Communities: CSHL Cancer Center Program > Cancer Genetics and Genomics Program
CSHL labs > Beyaz lab
CSHL labs > Westcott lab
SWORD Depositor: CSHL Elements
Depositing User: CSHL Elements
Date: 5 February 2026
Date Deposited: 11 Feb 2026 20:45
Last Modified: 11 Feb 2026 20:45
PMCID: PMC12878199
Related URLs:
URI: https://repository.cshl.edu/id/eprint/42074

Actions (login required)

Administrator's edit/view item Administrator's edit/view item